For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
18
views
58
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      484
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      NIR-IIb fluorescence-image guided synergistic surgery/starvation/chemodynamic therapy: an innovative treatment paradigm for malignant non-small cell lung cancers

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Currently, the prognosis and survival rate for patients bearing non-small cell lung cancer (NSCLC) is still quite poor, mainly due to lack of efficient theranostic paradigms to exert in time diagnostics and therapeutics.

          Methods: Herein, for NSCLC treatment, we offer a customized theranostic paradigm, termed NIR-IIb fluorescence diagnosis and synergistic surgery/starvation/chemodynamic therapeutics, with a newly designed theranostic nanoplatform PEG/MnCuDCNPs@GOx. The nanoplatform is composed of brightly NIR-II emissive downconversion nanoparticles (DCNPs)-core and Mn/Cu-silica shell loaded with glucose oxidase (GOx) to achieve synergistic starvation and chemodynamic therapy (CDT).

          Results: It is found that 10% Ce 3+ doped in the core and 100% Yb 3+ doped in the middle shell greatly improves the NIR-IIb emission up to even 20.3 times as compared to the core-shell DCNPs without Ce 3+ doping and middle shell. The bright NIR-IIb emission of the nanoplatform contributes to sensitive margin delineation of early-stage NSCLC (diameter < 1 mm) with a signal-to-background ratio (SBR) of 2.18, and further assists in visualizing drug distribution and guiding surgery/starvation/chemodynamic therapy. Notably, the starvation therapy mediated by GOx-driven oxidation reaction efficiently depletes intratumoral glucose, and supplies H 2O 2 to boost the CDT mediated by the Mn 2+ and Cu 2+, which consequently realized a highly effective synergistic treatment for NSCLC.

          Conclusion: This research demonstrates an efficient treatment paradigm for NSCLC with NIR-IIb fluorescence diganosis and image-guided synergistic surgery/starvation/chemodynamic therapeutics.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer Statistics, 2021

          Rebecca Siegel, Kimberly D Miller, Hannah Fuchs … (2021)
          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.
          Article 0 comments Cited 7933 times – based on 0 reviews     Review now
          Article has an altmetric score of 1609
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The biology and management of non-small cell lung cancer.

            Roy S. Herbst, Daniel Morgensztern, Chris Boshoff (2018)
            Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
            Article 0 comments Cited 1868 times – based on 0 reviews     Review now
            Article has an altmetric score of 272
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Recent Progress in Ferroptosis Inducers for Cancer Therapy

              Chen Liang, Xinglin Zhang, Mengsu Yang … (2019)
              Article 0 comments Cited 775 times – based on 0 reviews     Review now
              Article has an altmetric score of 8
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Theranostics
                Journal ID (iso-abbrev): Theranostics
                Journal ID (publisher-id): thno
                Title: Theranostics
                Publisher: Ivyspring International Publisher (Sydney )
                ISSN (Electronic): 1838-7640
                Publication date Collection: 2023
                Publication date (Electronic): 1 April 2023
                Volume: 13
                Issue: 7
                Pages: 2176-2191
                Affiliations
                [1 ]Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China. E-mail address: mengqw@hrbmu.edu.cn
                [2 ]School of Science, Shenzhen Key Laboratory of Flexible Printed Electronics Technology, Harbin Institute of Technology, Shenzhen 518055, China. E-mail address: guobing2020@hit.edu.cn
                [3 ]UTS-SUStech Joint Research Centre for Biomedical Materials and Devices, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China
                [4 ]Education Center and Experiments and Innovations, Harbin Institute of Technology, Shenzhen 518055, China
                [5 ]Institute of Biopharmaceutical and Health Engineering, Shenzhen Key Laboratory of Gene and Antibody Therapy, State Key Laboratory of Chemical Oncogenomics, Shenzhen International Graduate School, Tsinghua University, Shenzhen, Guangdong 518055, China
                [6 ]Department of Radiation Oncology, People's Hospital of Shenzhen Baoan District, The Second Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518100, China
                Author notes
                ✉ Corresponding authors: mengqw@ 123456hrbmu.edu.cn (Q. Meng), guobing2020@ 123456hit.edu.cn (B. Guo)

                #These authors contributed equally to this paper.

                Competing Interests: The authors have declared that no competing interest exists.

                Article
                Publisher ID: thnov13p2176
                DOI: 10.7150/thno.83753
                PMC ID: 10157733
                PubMed ID: 37153731
                SO-VID: 63eab962-e6bb-48e2-abff-a999820a8955
                Copyright © © The author(s)
                License:

                This is an open access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

                History
                Date received : 22 February 2023
                Date accepted : 22 March 2023
                Categories
                Subject: Research Paper

                ScienceOpen disciplines: Molecular medicine
                Keywords: downconversion nanoparticles,nir-ii fluorescence imaging,chemodynamic therapy,early tumors,non-small cell lung cancers
                Data availability:
                ScienceOpen disciplines: Molecular medicine
                Keywords: downconversion nanoparticles, nir-ii fluorescence imaging, chemodynamic therapy, early tumors, non-small cell lung cancers

                Comments

                Comment on this article